| Control Cycle 1 - Blood Volume - Control Group |
| Respondents |
Min. |
Max. |
CB |
CO |
| RESPONDENT 4 |
49.59 |
74,13 |
62.46 |
5.85 |
| RESPONDENT 5 |
9.50 |
30,16 |
18,19 |
3.16 |
| RESPONDENT 8 |
0.77 |
22.93 |
12.60 |
4.38 |
| RESPONDENT 9 |
1.82 |
20,41 |
13,14 |
2.56 |
| RESPONDENT 12 |
10.30 |
43.71 |
27.58 |
4.89 |
| RESPONDENT 13 |
10.88 |
31,22 |
17.99 |
3.40 |
| RESPONDENT 16 |
8.96 |
27.79 |
17.30 |
2.88 |
| RESPONDENT 17 |
21,29 |
95.30 |
57.70 |
11,13 |
| RESPONDENT 20 |
10.92 |
31.84 |
20.75 |
4.67 |
| RESPONDENT 21 |
9.25 |
39,16 |
18.55 |
5.37 |
| RESPONDENT 22 |
8.64 |
33,40 |
19.01 |
4.34 |
| CB |
12.90 |
40.91 |
25.93 |
4.78 |
| Control Cycle 2 - Blood Volume - Control Group |
| Respondents |
Min. |
Max. |
CB |
CO |
| RESPONDENT 4 |
14.46 |
41.74 |
28.73 |
4.29 |
| RESPONDENT 5 |
15,26 |
66.89 |
33.87 |
8.48 |
| RESPONDENT 8 |
3.18 |
29,44 |
20.70 |
5.40 |
| RESPONDENT 9 |
19.77 |
72,24 |
55.24 |
7.45 |
| RESPONDENT 12 |
11.64 |
36.53 |
24.78 |
3.23 |
| RESPONDENT 13 |
24,11 |
59.04 |
42.33 |
5.92 |
| RESPONDENT 16 |
13.78 |
46,64 |
27.38 |
6.59 |
| RESPONDENT 17 |
72.15 |
187.34 |
131.38 |
17.76 |
| RESPONDENT 20 |
8.67 |
46,48 |
35.73 |
0.17 |
| RESPONDENT 21 |
1.78 |
32.58 |
17.65 |
5.76 |
| RESPONDENT 22 |
16.01 |
53.38 |
36.89 |
6.47 |
| CB |
18.26 |
61.12 |
41.33 |
6.50 |
| Control Cycle 3 - Blood Amount - Control Group |
| Respondents |
Min. |
Max. |
CB |
CO |
| RESPONDENT 4 |
16,21 |
33,22 |
26.09 |
3.09 |
| RESPONDENT 5 |
13.67 |
49,10 |
32.50 |
6.33 |
| RESPONDENT 8 |
0.60 |
14.44 |
6.80 |
2.81 |
| RESPONDENT 9 |
22.43 |
117.95 |
79.86 |
16.81 |
| RESPONDENT 12 |
3.22 |
50,80 |
30.45 |
5.58 |
| RESPONDENT 13 |
12,11 |
63.93 |
31.71 |
13,23 |
| RESPONDENT 16 |
1.00 |
44,56 |
23.45 |
6.78 |
| RESPONDENT 17 |
15.68 |
87.64 |
51.35 |
11.80 |
| RESPONDENT 20 |
1.50 |
17.62 |
10.29 |
2.85 |
| RESPONDENT 21 |
11.80 |
23.55 |
17,18 |
2.10 |
| RESPONDENT 22 |
3.28 |
55.73 |
34.77 |
7.21 |
| CB |
9.23 |
50.78 |
31.31 |
7.14 |
| Control Cycle 4 - Blood Amount - Control Group |
| Respondents |
Min. |
Max. |
CB |
CO |
| RESPONDENT 4 |
26.98 |
55.92 |
45.36 |
5.09 |
| RESPONDENT 5 |
27,32 |
87.55 |
54.66 |
12.89 |
| RESPONDENT 8 |
1.49 |
34,49 |
22.00 |
6.92 |
| RESPONDENT 9 |
3.47 |
48.85 |
31.73 |
7.39 |
| RESPONDENT 12 |
29.90 |
90.79 |
59.73 |
9.68 |
| RESPONDENT 13 |
30,35 |
74.15 |
49.60 |
7.59 |
| RESPONDENT 16 |
14.00 |
43.71 |
30.02 |
4.80 |
| RESPONDENT 17 |
63.35 |
143.25 |
104.23 |
11.33 |
| RESPONDENT 20 |
2.59 |
36,33 |
21.76 |
6.21 |
| RESPONDENT 21 |
3.61 |
11.25 |
6.38 |
0.96 |
| RESPONDENT 22 |
18.58 |
65,61 |
39.60 |
7.41 |
| CB |
20.15 |
62.90 |
42.28 |
7.30 |
| Conclusion of development of required amount of blood - Control group |
|
|
|
| Cycle |
Min. |
Max. |
CB |
CO |
| Control cycle 1 |
12.90 |
40.91 |
25.93 |
4.78 |
| Control cycle 2 |
18,26 |
61,12 |
41.33 |
6.50 |
| Control cycle 3 |
9.23 |
50.78 |
31.31 |
7,14 |
| Control cycle 4 |
20.15 |
62.90 |
42.28 |
7.30 |
| CB |
15.13 |
53.93 |
35.22 |
6.43 |
The development of the measured values of the mean required amount of blood in subjects in the control group changes sporadically in each control cycle and there is no recognizable trend. The increase in the average required amount of blood in subjects in the control group in some control cycles is a consequence of the increase in the high fictitious value of circulation in some subjects.
The average minimum value of the required amount of blood in all control cycles lies in the subjects of the main group by more than 20%.
Subscribe to receive the latest updates on radiation protection and natural medicine.
No spam
Unsubscribe anytime
Share this knowledge
Help others learn more about natural space harmonization.
